c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis
出版年份 2021 全文链接
标题
c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis
作者
关键词
Mucosal melanoma, Acral lentiginous melanoma, KIT, Imatinib, Nilotinib, Dasatinib, Sunitinib, Meta-analysis
出版物
EUROPEAN JOURNAL OF CANCER
Volume 157, Issue -, Pages 348-357
出版商
Elsevier BV
发表日期
2021-09-23
DOI
10.1016/j.ejca.2021.08.015
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma
- (2020) Motoo Nomura et al. International Journal of Clinical Oncology
- CheckMate 067: Long-term outcomes in patients with mucosal melanoma.
- (2020) Alexander Noor Shoushtari et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
- (2020) Felicity Newell et al. Nature Communications
- Melanoma on Chronically Sun Damaged Skin: Lentigo Maligna and Desmoplastic Melanoma
- (2019) Madeline E. DeWane et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
- (2019) Da Meng et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
- (2019) Felicity Newell et al. Nature Communications
- Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
- (2019) Xinan Sheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma: What do all the mutations mean?
- (2018) Elizabeth J. Davis et al. CANCER
- Diagnosis and Management of Acral Lentiginous Melanoma
- (2018) Yoshiyuki Nakamura et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
- (2018) Julie Delyon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Mucosal Melanoma: a Literature Review
- (2018) Simon Skovsted Yde et al. Current Oncology Reports
- Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
- (2018) Omid Hamid et al. BRITISH JOURNAL OF CANCER
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma
- (2015) Elizabeth I. Buchbinder et al. CANCER
- Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
- (2015) R. D. Carvajal et al. CLINICAL CANCER RESEARCH
- Driver KIT mutations in melanoma cluster in four hotspots
- (2015) Nicolas Dumaz et al. MELANOMA RESEARCH
- Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)
- (2015) S. J. Lee et al. ONCOLOGIST
- A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
- (2013) A Adenis et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
- (2013) Michele Del Vecchio et al. EUROPEAN JOURNAL OF CANCER
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab for Patients With Advanced Mucosal Melanoma
- (2013) M. A. Postow et al. ONCOLOGIST
- Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
- (2011) Jin Hyun Cho et al. INVESTIGATIONAL NEW DRUGS
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 trial of dasatinib in advanced melanoma
- (2010) Harriet M. Kluger et al. CANCER
- Phase II trial of imatinib mesylate in patients with metastatic melanoma
- (2008) K B Kim et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now